trūFreeze® Spray Cryotherapy Patient Registry
To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.
Stenosis of Bronchus or Trachea
Central Airway Cancer
Device: truFreeze™ Spray Cryotherapy System
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration:||5 Years|
|Official Title:||trūFreeze® Spray Cryotherapy Patient Registry|
- Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings. [ Time Frame: 5 years ] [ Designated as safety issue: No ]The registry population consists of patients who are being treated using the trūFreeze® spray cryotherapy device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings.
- Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]All adverse events occurring during the registry period must be recorded. The clinical course of each event should be followed until resolution, stabilization, or until it has been determined that the registry treatment or participation is not the cause. Serious adverse events that are still ongoing at the end of the Spray Cryotherapy Patient Registry registry period must be followed up to determine the final outcome. Any serious adverse event that occurs after the registry period and is considered to be possibly related to the trūFreeze® spray cryotherapy device or registry participation should be recorded and reported immediately.
|Study Start Date:||April 2013|
|Estimated Study Completion Date:||April 2018|
|Estimated Primary Completion Date:||April 2018 (Final data collection date for primary outcome measure)|
trūFreeze® spray cryotherapy
Patients treated using the trūFreeze® spray cryotherapy device for the removal of unwanted tissue for conditions in the gastrointestinal and pulmonary setting.
|Device: truFreeze™ Spray Cryotherapy System|
This is a prospective, multi-center registry of patients who are currently undergoing spray cryotherapy using the trūFreeze® device. The registry population consists of patients who are being treated using the spray cryotherapy trūFreeze® device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings.
Patients eligible to participate in the registry will have disease and treatment specific data collected throughout therapy and long-term follow-up. Subjects will be considered to have completed the registry when data from the 5 year follow-up visit has been collected. The beginning of the follow-up period commences with the first endoscopic treatment session.
Subjects may be withdrawn prior to this for any of the following reasons:
- Death, or
- Lost to Follow-Up, or
- Withdrawal of consent, or
- Discontinuation by the investigator. Three attempts at contact using two different methods are required prior to determination that the subject is lost to follow-up. Attempts at contact must be with certified letters OR documented telephone contact.
The registry will utilize electronic case report forms using a web-based platform housed at the University of North Carolina at Chapel Hill. Access to the database will be limited to individuals involved in the research registry and will require a unique user ID and password. All access to the database and web-based application will be encrypted (HTTPS) and electronic systems compliant with applicable privacy and security regulations. To maintain patient confidentiality, all subjects will be assigned a registry identification number, and this will be the only link between subject identity and treatment information. Read-only access will be provided to any personnel who is not an administrator or responsible for data entry.
All data requested on the case report form must be recorded. All missing data must be explained. The system allows sites to directly enter data electronically, however sites are still responsible for ensuring they have source documents that support all data entered electronically that are separate and verifiable. The registry system will maintain an audit trail that captures when electronic entries are changed, what the change was, and who made the change.
The investigators will ensure the capability for inspections of applicable registry-related facilities (e.g. pharmacy, diagnostic laboratory, etc.). The registry will be monitored by the sponsor, and allow auditing by the Institutional Review Board, government regulatory bodies, and University compliance and quality assurance groups of all registry related documents (e.g. source documents, regulatory documents, data collection instruments, registry data, etc.).
|United States, Maryland|
|University of Maryland||Recruiting|
|Baltimore, Maryland, United States, 21210|
|Contact: Bruce Greenwald, MD 410-328-8731 firstname.lastname@example.org|
|Contact: Ashutosh Sachdeva, MBBS 410-328-8141 email@example.com|
|Principal Investigator: Bruce Greenwald, MD|
|Sub-Investigator: Ashutosh Sachdeva, MBBS|
|Walter Reed National Military Medical Center||Not yet recruiting|
|Bethesda, Maryland, United States, 20889|
|Contact: Robert Browning, MD 301-295-4233 firstname.lastname@example.org|
|Principal Investigator: Robert Browning, MD|
|United States, North Carolina|
|University of North Carolina at Chapel Hill||Recruiting|
|Chapel Hill, North Carolina, United States, 27599|
|Contact: Susan Moist, MS 919-843-2508 email@example.com|
|Principal Investigator: Nicholas J Shaheen, MD, MPH|
|United States, South Carolina|
|Medical University of South Carolina||Recruiting|
|Charleston, South Carolina, United States, 29425|
|Contact: Brenda Hoffman, MD 843-876-4265 firstname.lastname@example.org|
|Contact: Cecilia Wright, BS 843-876-2184|
|Principal Investigator: Brenda Hoffman, MD|
|Principal Investigator:||Nicholas Shaheen, MD||University of North Carolina, Chapel Hill|
|Study Director:||Ellen Sheets, MD||CSA Medical, Inc.|